Sucampo's constipation drug Amitiza under review in Canada
This article was originally published in Scrip
Executive Summary
Health Canada has accepted for review Sucampo Pharmaceuticals' application to market Amitiza (lubiprostone) as a treatment for chronic idiopathic constipation (CIC) in adults and opioid induced constipation (OIC) in adults with chronic non-cancer pain.